CRISPR Therapeutics AG 8-K

What Happened
CRISPR Therapeutics AG filed an 8-K on January 12, 2026 announcing a press release with program updates across its in vivo gene editing, CAR‑T (zugo‑cel) and regenerative medicine portfolios. Key clinical highlights include positive Phase 1 data for CTX310 (ANGPTL3) presented in 2025 and advancement to Phase 1b, CTX320 (LPA) dose‑escalation reductions up to 73% and a next‑generation CTX321 showing ~2x greater potency in preclinical testing, and continued progress of zugo‑cel (formerly CTX112) in multiple autoimmune and hematologic malignancy trials. The company also reported regenerative program progress with CTX211 showing detectable C‑peptide at 12 months and a move to a next‑generation candidate, CTX213.

Key Details

• Filing date: January 12, 2026 (Current Report on Form 8‑K).
• CTX310 (ANGPTL3): positive Phase 1 results in 2025 (deep, durable triglyceride and LDL reductions after single IV course); advanced to Phase 1b for severe hypertriglyceridemia and refractory hypercholesterolemia.
• CTX320/CTX321 (LPA): CTX320 showed up to 73% reduction in dose escalation; CTX321 (next‑gen guide RNA) ~2x potency in preclinical studies and is in IND/CTA‑enabling studies.
• Zugo‑cel (CTX112): ongoing Phase 1 trials in SLE, SSc, inflammatory myositis, ITP and wAIHA; first SLE patient drug‑free DORIS remission through month 9; second SLE patient SLEDAI‑2K = 0 through month 2; Phase 1/2 in B‑cell malignancies ongoing; collaboration with Eli Lilly to test zugo‑cel + pirtobrutinib in aggressive B‑cell lymphomas.
• Regenerative: CTX211 showed detectable C‑peptide at 12 months post‑implantation; CTX213 (next‑generation hypoimmune candidate) progressing toward clinic.
• Additional preclinical programs advancing: CTX460 (SERPINA1 for AATD) and CTX340 (AGT for refractory hypertension) in preclinical/IND‑enabling stages.

Why It Matters
These updates show pipeline progression across multiple therapeutic areas—cardiovascular, autoimmune, oncology and regenerative medicine—which can drive future clinical value inflection points. Positive early clinical signals (CTX310, CTX320/321, zugo‑cel) and a collaboration with Eli Lilly may expand development options and external validation for certain programs. The filing contains no new financial results; investors should note these are program updates and subject to usual clinical and regulatory risks described in the company’s public filings.